BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) today announced that updated preliminary clinical trial results from the Phase I study of VQD-002 (triciribine phosphate, TCN-P) for advanced hematological malignancies will be presented at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, GA, on Saturday, December 8, 2007.
